STI Stock Trade Intelligence
MAP

MICROBA LIFE SCIENCES LIMITED

Health Care · ASX:MAP
$0.0360
0.00%
Trading halt
Market cap
$27M
Turnover
—
Last price
$0.0360
Day change
0.00%
Announcements
21
Range, past year
Open 0.073 · Low 0.033 · Now 0.036 · High 0.225
Open MAP in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

MAP momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
25/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+5.9%
1 Month
-18.2%
1 Year
-50.0%
RSI
39
Avg daily range
5.7%

MICROBA LIFE SCIENCES LIMITED scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.88 — highly linear uptrend
Points to watch
  • 60d drawdown -40.4%
  • Risk rating: Very High
  • Composite downside risk elevated
MAP appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

MAP announcements

Recent price-sensitive releases.
  • 2026-11-13 TOV: GSS - Panel Receives Application Scheme of Arrangement | Takeover - Other
  • 2026-11-13 Trading Halt Trading Halt
  • 2026-11-13 Pause in Trading Notice Pending
  • 2026-10-21 Update on Commercial Terms for the Proposed Merger with MAP Scheme of Arrangement
  • 2026-10-20 Q1 FY27 Quarterly Activities Report & Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-20 Microba secures $2m placement and increases cost reductions Trading Update | Placement | Director Appointment/Resignation
  • 2026-09-25 Appointment of Interim Chief Executive Officer CEO/Managing Director - Appointment Resignation | Company Administration - Other
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.